Fundraising Fox

Mesenbio

3 known investors

Mesenbio develops extracellular vesicle (EV) therapeutics derived from mesenchymal stem cells, using its FT-01 platform to enable scalable, GMP-ready EV manufacturing for regenerative medicine. The company is advancing a licensing-ready production platform and preclinical therapeutic candidate (MEV-N01) targeting rheumatoid arthritis.

BiotechHealthtechLongevity

Founders & leadership

DD
Dr. David KuntinChief Executive Officer
PP
Prof. Paul GeneverinChief Scientific Officer
AAAnita Adams
Anita AdamsinFinance Director

Board

DDDr. David Simpson
Dr. David SimpsonChair
JGJason Goldstein
Jason GoldsteinBoard director

Investors · 3

DSW VenturesManchester · $130K – $1.3M
Innovate UKreportedLondon

Also in the syndicate · 1

NG Bio

In the news

Innovative Approach to Combat Arthritis: Mesenbio's Stem Cell Therapybiopharmatrend.com · Jan 2024Mesenbio raises £1.4m to develop therapeutic pipeline for arthritis treatment - SETsquaredsetsquared.co.uk · Jan 2024Mesenbio, a University of York spin-out, receives £1.4m | York Pressyorkpress.co.uk · Jan 2024University spin-out raises £1.4m for novel arthritis treatment | TheBusinessDesk.comthebusinessdesk.com · Jan 2024Mesenbio Raises £1.4M in Fundingfinsmes.com · Jan 2024Press Release: Mesenbio raises £1.4M to develop therapeutic pipeline — Mesenbiomesenbio.net · Jan 2024

Frequently asked questions

What does Mesenbio do?
Mesenbio develops extracellular vesicle (EV) therapeutics derived from mesenchymal stem cells, using its FT-01 platform to enable scalable, GMP-ready EV manufacturing for regenerative medicine. The company is advancing a licensing-ready production platform and preclinical therapeutic candidate (MEV-N01) targeting rheumatoid arthritis.
Who are Mesenbio's investors?
Mesenbio's investors include DSW Ventures, Innovate UK.